Posted by Michael Wonder on 24 Oct 2025
Biocon Biologics receives Health Canada spproval for Yesintek and Yesintek I.V. (ustekinumab), a biosimilar to Stelara
23 October 2025 - Biocon Biologics today announced that Health Canada has granted a notice of compliance for Yesintek (ustekinumab injection) and Yesintek I.V. (ustekinumab for injection, solution for intravenous infusion), a biosimilar to Stelara (ustekinumab injection) and Stelara I.V. (ustekinumab for injection, solution for intravenous infusion).
The approval was granted on 17 October, paving the way for Canadian commercial availability in mid October.
